{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:24:38Z","timestamp":1794558278026,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015756","name":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","award":["IN-ES-380-5729"],"award-info":[{"award-number":["IN-ES-380-5729"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijantimicag.2026.107825","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:42:47Z","timestamp":1777308167000},"page":"107825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and tolerability of switching to bictegravir\/emtricitabine\/tenofovir alafenamide versus continuing dolutegravir\/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-7135","authenticated-orcid":false,"given":"Ignacio","family":"Perez-Valero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Corona Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jose","family":"Crussells Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-2095","authenticated-orcid":false,"given":"Maria","family":"Velasco Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Mican Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Nicolas","family":"Navarrete-Lorite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-873X","authenticated-orcid":false,"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7993-306X","authenticated-orcid":false,"given":"Julia","family":"Barrado-Cuchillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Molero Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Artigues Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Mena de Cea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"de la Fuente Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-1953","authenticated-orcid":false,"given":"Xavier","family":"Perez Stachowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-6107","authenticated-orcid":false,"given":"Lucio Jesus","family":"Garcia Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-2203","authenticated-orcid":false,"given":"Mariana","family":"Diaz Almidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ferreira Tata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ijantimicag.2026.107825_bib0001","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on Life Expectancy of HIV-1 Positive Individuals of CD4+ Cell Count and Viral Load Response to Antiretroviral Therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107825_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40263-013-0132-4","article-title":"Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs","volume":"28","author":"Abers","year":"2014","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107825_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A Clinical Review of HIV Integrase Strand Transfer Inhibitors (INSTIs) for the Prevention and Treatment of HIV-1 Infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107825_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized Trials","volume":"13","author":"Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"10.1016\/j.ijantimicag.2026.107825_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"Perez-Valero","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10.1016\/j.ijantimicag.2026.107825_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa482","article-title":"Randomized Trial Evaluating the Neurotoxicity of Dolutegravir\/Abacavir\/Lamivudine and Its Reversibility After Switching to Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide: GESIDA 9016","volume":"7","author":"Perez Valero","year":"2020","journal-title":"Open Forum Infect Dis."},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107825_bib0007","doi-asserted-by":"crossref","first-page":"ofac345","DOI":"10.1093\/ofid\/ofac345","volume":"9","author":"Cabello-Ubeda","year":"2022","journal-title":"Open Forum Infect Dis."},{"issue":"12","key":"10.1016\/j.ijantimicag.2026.107825_bib0008","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1093\/jac\/dkad338","article-title":"Tolerability of Bictegravir\/Tenofovir Alafenamide\/Emtricitabine Versus Dolutegravir\/Lamivudine as Maintenance Therapy in a Real-Life Setting","volume":"78","author":"Rocabert","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2026.107825_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291480","article-title":"Effectiveness, Durability and Safety of Dolutegravir and Lamivudine Versus Bictegravir, Emtricitabine and Tenofovir Alafenamide in a Real-World Cohort of HIV-infected Adults","volume":"18","author":"Mendoza","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijantimicag.2026.107825_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher Rates of Neuropsychiatric Adverse Events Leading to Dolutegravir Discontinuation in Women and Older Patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107825_bib0011","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide From Dolutegravir-Based Therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107825_bib0012","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3851\/IMP3351","article-title":"Short-Term Neuropsychiatric Tolerability of Bictegravir Combined With Emtricitabine\/Tenofovir Alafenamide in Clinical Practice","volume":"25","author":"Hoffmann","year":"2020","journal-title":"Antivir Ther"},{"issue":"10107","key":"10.1016\/j.ijantimicag.2026.107825_bib0013","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Dolutegravir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection (GS-US-380-1489): A Double-Blind, Multicentre, Phase 3, Randomised Controlled Non-Inferiority Trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijantimicag.2026.107825_bib0014","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jmii.2023.01.015","article-title":"Patient-Reported Outcomes Among Virally Suppressed People Living With HIV After Switching to Co-Formulated Bictegravir, Emtricitabine and Tenofovir Alafenamide","volume":"56","author":"Chen","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"10.1016\/j.ijantimicag.2026.107825_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02038-21","article-title":"Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro","volume":"66","author":"Acosta","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2026.107825_bib0016","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000004171","article-title":"Outcomes in People With HIV Who Resume or Switch to Bictegravir\/FTC\/TAF Following a Treatment Interruption","volume":"39","author":"Moyle","year":"2025","journal-title":"AIDS."},{"issue":"7","key":"10.1016\/j.ijantimicag.2026.107825_bib0017","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/sextrans-2024-056202","article-title":"B\/F\/TAF Forgiveness to Non-Adherence","volume":"100","author":"Maggiolo","year":"2024","journal-title":"Sex Transm Infect."},{"key":"10.1016\/j.ijantimicag.2026.107825_bib0018","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ijantimicag.2026.107825_bib0019","article-title":"Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial","volume":"16","author":"L'hostellier","year":"2026","journal-title":"BMJ Open"},{"issue":"10528","key":"10.1016\/j.ijantimicag.2026.107825_bib0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(25)01948-8","volume":"407","author":"Colson","year":"2026","journal-title":"Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:12:01Z","timestamp":1794557521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0924857926001147"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107825","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of switching to bictegravir\/emtricitabine\/tenofovir alafenamide versus continuing dolutegravir\/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107825"}}